Literature DB >> 1321290

Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins.

M Scheffner1, T Takahashi, J M Huibregtse, J D Minna, P M Howley.   

Abstract

The E6 oncoproteins encoded by the cancer-associated human papillomaviruses (HPVs) can associate with and promote the degradation of wild-type p53 in vitro. To gain further insight into this process, the ability of HPV-16 E6 to complex with and promote the degradation of mutant forms of p53 was studied. A correlation between binding and the targeted degradation of p53 was established. Mutant p53 proteins that bound HPV-16 E6 were targeted for degradation, whereas those that did not complex HPV-16 E6 were not degraded. Since the HPV-16 E6-promoted degradation involves the ubiquitin-dependent proteolysis pathway, specific mutations were made in the amino terminus of p53 to examine whether the E6 targeted degradation involved the N-end rule pathway. No requirement for destabilizing amino acids at the N terminus of p53 was found, nor was evidence found that HPV-16 E6 could provide this determinant in trans, indicating that the N-terminal rule pathway is not involved in the E6-promoted degradation of p53.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1321290      PMCID: PMC241378     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  p53 point mutation in HPV negative human cervical carcinoma cell lines.

Authors:  T Crook; D Wrede; K H Vousden
Journal:  Oncogene       Date:  1991-05       Impact factor: 9.867

3.  Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines.

Authors:  D Wrede; J A Tidy; T Crook; D Lane; K H Vousden
Journal:  Mol Carcinog       Date:  1991       Impact factor: 4.784

4.  The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines.

Authors:  M Scheffner; K Münger; J C Byrne; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

5.  Cyclin is degraded by the ubiquitin pathway.

Authors:  M Glotzer; A W Murray; M W Kirschner
Journal:  Nature       Date:  1991-01-10       Impact factor: 49.962

6.  In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential.

Authors:  M S Barbosa; W C Vass; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

7.  Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells.

Authors:  V Band; J A De Caprio; L Delmolino; V Kulesa; R Sager
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

8.  Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells.

Authors:  M Oren; W Maltzman; A J Levine
Journal:  Mol Cell Biol       Date:  1981-02       Impact factor: 4.272

9.  A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18.

Authors:  J M Huibregtse; M Scheffner; P M Howley
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

10.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

Authors:  J V Gannon; R Greaves; R Iggo; D P Lane
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

View more
  40 in total

1.  Both conserved region 1 (CR1) and CR2 of the human papillomavirus type 16 E7 oncogene are required for induction of epidermal hyperplasia and tumor formation in transgenic mice.

Authors:  G A Gulliver; R L Herber; A Liem; P F Lambert
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase.

Authors:  S Nakagawa; J M Huibregtse
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

3.  Polyubiquitination by HECT E3s and the determinants of chain type specificity.

Authors:  Hyung Cheol Kim; Jon M Huibregtse
Journal:  Mol Cell Biol       Date:  2009-04-13       Impact factor: 4.272

Review 4.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

5.  Human papillomavirus type 16 E7 oncoprotein upregulates the retinoic acid receptor-beta expression in cervical cancer cell lines and K14E7 transgenic mice.

Authors:  Jorge Gutiérrez; Enrique García-Villa; Rodolfo Ocadiz-Delgado; Enoc M Cortés-Malagón; Juan Vázquez; Alejandra Roman-Rosales; Elizabeth Alvarez-Rios; Haydar Celik; Marta C Romano; Aykut Üren; Paul F Lambert; Patricio Gariglio
Journal:  Mol Cell Biochem       Date:  2015-07-15       Impact factor: 3.396

6.  Viral oncoproteins discriminate between p53 and the p53 homolog p73.

Authors:  M C Marin; C A Jost; M S Irwin; J A DeCaprio; D Caput; W G Kaelin
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

7.  Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability.

Authors:  M H Kubbutat; K H Vousden
Journal:  Mol Cell Biol       Date:  1997-01       Impact factor: 4.272

Review 8.  Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.

Authors:  Lindsey N Micel; John J Tentler; Peter G Smith; Gail S Eckhardt
Journal:  J Clin Oncol       Date:  2013-01-28       Impact factor: 44.544

9.  The myxoma virus m-t5 ankyrin repeat host range protein is a novel adaptor that coordinately links the cellular signaling pathways mediated by Akt and Skp1 in virus-infected cells.

Authors:  Steven J Werden; Jerry Lanchbury; Donna Shattuck; Chris Neff; Max Dufford; Grant McFadden
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

10.  Involvement of the proteasome and antizyme in ornithine decarboxylase degradation by a reticulocyte lysate.

Authors:  Y Murakami; S Matsufuji; K Tanaka; A Ichihara; S Hayashi
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.